CRISPR Therapeutics AG (CRSP) EPS (Weighted Average and Diluted) (2018 - 2025)
Historic EPS (Weighted Average and Diluted) for CRISPR Therapeutics AG (CRSP) over the last 8 years, with Q3 2025 value amounting to -$1.17.
- CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) fell 1584.16% to -$1.17 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.57, marking a year-over-year decrease of 9892.86%. This contributed to the annual value of -$4.84 for FY2024, which is 14928.28% down from last year.
- Per CRISPR Therapeutics AG's latest filing, its EPS (Weighted Average and Diluted) stood at -$1.17 for Q3 2025, which was down 1584.16% from -$2.4 recorded in Q2 2025.
- In the past 5 years, CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) registered a high of $9.44 during Q2 2021, and its lowest value of -$2.4 during Q2 2022.
- For the 5-year period, CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) averaged around -$0.83, with its median value being -$1.43 (2024).
- As far as peak fluctuations go, CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) skyrocketed by 82615.38% in 2021, and later crashed by 18288.84% in 2024.
- Over the past 5 years, CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) (Quarter) stood at -$1.74 in 2021, then grew by 19.54% to -$1.4 in 2022, then soared by 180.71% to $1.13 in 2023, then tumbled by 182.89% to -$0.94 in 2024, then decreased by 24.91% to -$1.17 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$1.17 for Q3 2025, versus -$2.4 for Q2 2025 and -$1.58 for Q1 2025.